Suppr超能文献

一种离子交换水软化器预防新生儿特应性皮炎的盲法随机对照试验的方案,该试验嵌入了一项机制研究:用于预防特应性皮炎的软化水(SOFTER)试验。

Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial.

机构信息

Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK.

Women's Health, King's College London, London, UK.

出版信息

BMJ Open. 2019 Aug 20;9(8):e027168. doi: 10.1136/bmjopen-2018-027168.

Abstract

INTRODUCTION

Atopic eczema affects 20% of UK children, and environmental factors are important in its aetiology. Several observational studies suggest an increased risk of atopic eczema in children living in hard water areas. The Softened Water for Eczema Prevention pilot trial tests the feasibility of installing domestic ion-exchange water softeners around the time of birth to reduce the risk of atopic eczema in children with a family history of atopy. A further aim is to explore the pathophysiological mechanisms for this in an embedded mechanistic study.

METHODS AND ANALYSIS

Multicentre parallel group assessor-blinded randomised controlled pilot trial. Participants are newborn babies (n=80) living in a hard water (>250 mg/L calcium carbonate) area at risk of developing atopic eczema because of a family history of atopy. Participants will be randomised prior to birth in a 1:1 ratio. The intervention group will have an ion-exchange water softener installed prior to birth. The control group will receive their usual domestic hard water supply. Follow-up will be until 6 months of age. Data will be collected at birth (baseline), 1, 3 and 6 months of age. The main outcome is the proportion of eligible families screened who are willing and able to be randomised. Several secondary feasibility and clinical endpoints will also be evaluated, alongside mechanistic outcomes. Data will be analysed on an intention-to-treat basis. There will be no hypothesis testing for the clinical outcomes. Study acceptability will be evaluated through semistructured interviews.

ETHICS AND DISSEMINATION

This study has been reviewed and given a favourable opinion by the North West-Liverpool East Research Ethics Committee (Ref: 17/NW/0661). The results of the study will be reported at international conferences and in peer-reviewed scientific journals. We will send participating families a summary of the pilot trial results.

TRIAL REGISTRATION NUMBER

NCT03270566.

摘要

引言

特应性皮炎影响了英国 20%的儿童,环境因素在其发病机制中起着重要作用。几项观察性研究表明,生活在硬水区的儿童患特应性皮炎的风险增加。“预防特应性皮炎软化水”试点试验旨在测试在出生前后安装家用离子交换水软化器以降低特应性家族史儿童特应性皮炎风险的可行性。其进一步目的是在一项嵌入式机制研究中探索这种方法的病理生理学机制。

方法和分析

多中心平行组评估员盲法随机对照试点试验。参与者为居住在硬水(>250mg/L 碳酸钙)地区的新生儿(n=80),他们有特应性家族史,因此有发展特应性皮炎的风险。参与者将在出生前按 1:1 的比例随机分组。干预组将在出生前安装离子交换水软化器。对照组将接受其常规家用硬水供应。随访至 6 个月龄。数据将在出生时(基线)、1 个月、3 个月和 6 个月龄收集。主要结局是筛查出有资格的家庭中愿意和能够进行随机分组的比例。还将评估几个次要的可行性和临床终点,以及机制终点。将按意向治疗进行数据分析。对于临床结局,将不会进行假设检验。通过半结构化访谈评估研究的可接受性。

伦理和传播

本研究已通过西北-利物浦东研究伦理委员会审查并给予有利意见(Ref: 17/NW/0661)。该研究的结果将在国际会议上和同行评议的科学期刊上报告。我们将向参与家庭发送试点试验结果的摘要。

试验注册号

NCT03270566。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c4/6707708/20e1d6110bf9/bmjopen-2018-027168f01.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验